CSL (OTCMKTS:CSLLY) Rating Increased to Strong-Buy at The Goldman Sachs Group

CSL (OTCMKTS:CSLLY) was upgraded by equities researchers at The Goldman Sachs Group to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

CSL Stock Performance

Shares of OTCMKTS CSLLY opened at $86.16 on Thursday. The business has a 50 day moving average price of $89.07 and a two-hundred day moving average price of $96.47. CSL has a fifty-two week low of $83.31 and a fifty-two week high of $109.00. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.97 and a current ratio of 2.18.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.